Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Asenapine Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy PG058

    Asenapine (Saphris) Coverage

    Customize your policy alerts

    Sign up for Oscar Health Policy PG058 alerts

    Get alerted when Policy PG058 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity criteria for generic asenapine and brand Saphris for specified psychiatric conditions, including bipolar disorder, postpartum psychosis, schizophrenia, schizoaffective disorder, and severe agitation or aggression.

    Policy Summary
    PayerOscar Health
    PolicyAsenapine (Saphris) Coverage
    Policy CodePolicy PG058
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit current chart notes and relevant test results or imaging reports supporting the diagnosis and prior treatment history.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10+Minimum age for bipolar disorder
    18+Minimum age for other covered indications
    1Bipolar alternatives required
    2Schizophrenia alternatives required
    7 daysInitial agitation/aggression authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    14 daysReauthorization period

    Coverage Criteria

    General Medical Necessity Criteria

    Asenapine (Saphris) is medically necessary when ALL of the following criteria are met:

    ALL of the following

    • The requested medication is prescribed by or in consultation with a psychiatrist.
    • IF the request is for brand Saphris, the member is unable to use, or has tried and failed generic asenapine.
    • Asenapine (Saphris) is being prescribed at a dose and frequency that is within FDA-approved labeling OR is supported by compendia or evidence-based published dosing guidelines for the requested indication.
    • The member meets the applicable Medical Necessity Criteria for Initial Clinical Review or Subsequent Clinical Review listed below.

    Initial Therapy — Bipolar Disorder

    Asenapine (Saphris) is medically necessary when ALL of the following criteria are met:

    ALL of the following

    • The member meets the above General Medical Necessity Criteria.
    • The member is 10 years of age or older.>= 10 years
    • The member has a diagnosis of bipolar disorder.
    • ONE of the following

      • The member is unable to use, or has tried and failed aripiprazole (Abilify).
      • The member is unable to use, or has tried and failed lurasidone (Latuda).

    Initial Therapy — Postpartum Psychosis

    Asenapine (Saphris) is medically necessary when ALL of the following criteria are met:

    ALL of the following

    • The member meets the above General Medical Necessity Criteria.
    • The member has postpartum psychosis as evidenced by ONE of the following

      • New-onset psychotic symptoms (e.g., delusions, disorganized thoughts, hallucinations, agitation, or bizarre behavior) in the postpartum period.
      • Bipolar disorder with postpartum psychotic features (e.g., delusions, disorganized thoughts, hallucinations, agitation, or bizarre behavior).
      • A primary mental disorder with psychotic symptoms during the peripartum period.

    Initial Therapy — Schizophrenia

    Asenapine (Saphris) is medically necessary when ALL of the following criteria are met:

    ALL of the following

    • The member meets the above General Medical Necessity Criteria.
    • The member is 18 years of age or older.>= 18 years
    • The member has a diagnosis of schizophrenia.
    • TWO of the following

      • The member is unable to use, or has tried and failed aripiprazole (Abilify).

    Initial Therapy — Schizoaffective Disorder

    Asenapine (Saphris) is medically necessary when ALL of the following criteria are met:

    ALL of the following

    • The member meets the above General Medical Necessity Criteria.
    • The member is 18 years of age or older.>= 18 years
    • The member has a diagnosis of schizoaffective disorder.
    • The member is unable to use or has tried and failed paliperidone.
    • ONE of the following

    Initial Therapy — Agitation/Aggression

    Asenapine (Saphris) is medically necessary when ALL of the following criteria are met:

    ALL of the following

    • The member meets the above General Medical Necessity Criteria.
    • The member is 18 years of age or older.>= 18 years
    • The member has severe agitation/aggression requiring pharmacotherapy associated with ONE of the following

      • A psychiatric disorder (e.g., bipolar disorder or schizophrenia).
      • Substance intoxication.

    Subsequent Therapy — Agitation/Aggression

    Asenapine (Saphris) is medically necessary for subsequent therapy when ALL of the following criteria are met. If met, the requested product will be authorized for up to 14 days.

    ALL of the following

    • The member meets the above applicable General Medical Necessity Criteria.
    • Documentation indicates that the member's symptoms have responded (i.e., improvement in agitation/aggression symptoms), but aggressive behavior is not yet fully resolved or controlled.

    Other Indications

    Asenapine (Saphris) is not medically necessary for indications other than those described in the applicable coverage criteria above.

    Asenapine (Saphris) for any other indication is not covered as medically necessary.

    Asenapine (Saphris) for any other indication is considered experimental, investigational, or unproven.

    Provider Actions and Review Requirements

    Prior Authorization

    Psychiatrist and Appropriate Dosing Required

    Before requesting authorization, ensure the medication is prescribed by or in consultation with a psychiatrist and that the requested dose and frequency are within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the indication.

    Step Therapy

    Generic Asenapine Required Before Brand Saphris

    For a request for brand Saphris, document that the member is unable to use generic asenapine or has tried and failed generic asenapine.

    Prior Authorization

    Indication-Specific Approval Criteria

    Authorization requires satisfaction of the applicable indication-specific criteria in addition to the general criteria. Submit documentation supporting the diagnosis, applicable age requirement, required prior treatment, and any indication-specific clinical circumstances.

    Clinical Background

    Asenapine is a second-generation, or atypical, antipsychotic used to treat schizophrenia and bipolar I disorder. This guideline also addresses postpartum psychosis and severe agitation or aggression associated with psychiatric disorders, substance intoxication, or organic causes. Treatment selection should consider prior response, safety, tolerability, and patient-specific factors, and may include medication and nonmedication approaches.

    Definitions

    Bipolar disorder
    DefinitionA mental health condition that includes episodes of emotional highs, such as mania, and lows, such as depression.
    Potential effectsMay cause extreme changes in behavior and mood, such as feeling much happier or sadder than normal.
    Policy relevanceBipolar disorder is an indication addressed by the asenapine (Saphris) coverage criteria.
    Postpartum psychosis
    DefinitionA rare but serious mental health emergency characterized by sudden onset of psychotic symptoms shortly after childbirth.
    Possible symptomsMay include acute-onset delusions, disorganized thoughts, hallucinations, and/or agitation.

    Initial Therapy Criteria

    General initial-therapy requirements

    All requests must meet ALL of these general requirements.

    General initial-therapy requirements: The medication is prescribed by or in consultation with a psychiatrist; for brand Saphris, the member is unable to use or has tried and failed generic asenapine; the dose and frequency are within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines; and the applicable indication-specific criteria are met.

    Bipolar disorder

    Bipolar disorder initial therapy requires ALL listed criteria.

    • ONE listed alternative: The member is unable to use, or has tried and failed, aripiprazole, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.1 alternative

    Continuation Therapy Criteria

    Agitation/aggression continuation

    For subsequent clinical review of agitation/aggression, ALL criteria must be met.

    Agitation/aggression continuation: The member meets the applicable general medical-necessity criteria, and documentation indicates that symptoms have responded with improvement in agitation/aggression but aggressive behavior is not yet fully resolved or controlled.Up to 14 days

    Required Prior Therapy

    IndicationStep-therapy requirement
    Bipolar disorderUnable to use or tried and failed ONE of: aripiprazole, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.
    IndicationStep-therapy requirement
    SchizophreniaUnable to use or tried and failed TWO of: aripiprazole, lurasidone, clozapine, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.
    IndicationStep-therapy requirement
    Schizoaffective disorderUnable to use or tried and failed paliperidone PLUS ONE of: aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, or ziprasidone.
    IndicationFirst-line acute-treatment pathwayAlternative pathway
    Severe agitation/aggressionUnable to use or tried and failed first-line immediate-acting intramuscular medications, such as aripiprazole IM, lorazepam IM, olanzapine IM, or ziprasidone IM; or inhaled loxapine.For milder symptoms, the member is willing to take oral medication.

    Authorization Duration Limits

    Initial authorization quantity limit
    MedicationAsenapine (Saphris)
    Authorization typeInitial agitation/aggression authorization
    Quantity limitUp to 7 days per course
    Reauthorization quantity limit
    MedicationAsenapine (Saphris)
    Authorization typeSubsequent agitation/aggression authorization
    Quantity limitUp to 14 days per course when reauthorization criteria are met
    Policy Summary
    PayerOscar Health
    PolicyAsenapine (Saphris) Coverage
    Policy CodePolicy PG058
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit current chart notes and relevant test results or imaging reports supporting the diagnosis and prior treatment history.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Review RequirementsClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaRequired Prior TherapyAuthorization Duration Limits
    The member is unable to use, or has tried and failed olanzapine (Zyprexa).
  1. The member is unable to use, or has tried and failed paliperidone (Invega).
  2. The member is unable to use, or has tried and failed quetiapine (Seroquel).
  3. The member is unable to use, or has tried and failed risperidone (Risperdal).
  4. The member is unable to use, or has tried and failed ziprasidone (Geodon).
  5. The member is unable to use, or has tried and failed lurasidone (Latuda).
  6. The member is unable to use, or has tried and failed clozapine (Clozaril).
  7. The member is unable to use, or has tried and failed olanzapine (Zyprexa).
  8. The member is unable to use, or has tried and failed paliperidone (Invega).
  9. The member is unable to use, or has tried and failed quetiapine (Seroquel).
  10. The member is unable to use, or has tried and failed risperidone (Risperdal).
  11. The member is unable to use, or has tried and failed ziprasidone (Geodon).
  12. The member is unable to use or has tried and failed aripiprazole (Abilify).
  13. The member is unable to use or has tried and failed lurasidone (Latuda).
  14. The member is unable to use or has tried and failed olanzapine (Zyprexa).
  15. The member is unable to use or has tried and failed quetiapine (Seroquel).
  16. The member is unable to use or has tried and failed risperidone (Risperdal).
  17. The member is unable to use or has tried and failed ziprasidone (Geodone).
  18. Other organic causes (e.g., central nervous system diseases including Parkinson's disease, Alzheimer's disease, other dementias, encephalitis, meningitis, or brain trauma).
  19. The member has not responded to less invasive management strategies, such as verbal de-escalation.
  20. The member is characterized by ONE of the following

    • The member is unable to use, or has tried and failed first-line immediate-acting intramuscular medications (e.g., aripiprazole IM, lorazepam IM, olanzapine IM, or ziprasidone IM) or inhaled medications (e.g., loxapine inhaled).
    • The member exhibits milder symptoms and is willing to take oral medication.
  21. Chart documentation is provided detailing the symptoms and management that support the criteria above.
    • Bipolar disorder: age 10 or older, bipolar diagnosis, and one required formulary alternative.
    • Postpartum psychosis: new-onset postpartum psychotic symptoms, bipolar disorder with postpartum psychotic features, or a primary mental disorder with peripartum psychotic symptoms.
    • Schizophrenia: age 18 or older, schizophrenia diagnosis, and two required formulary alternatives.
    • Schizoaffective disorder: age 18 or older, schizoaffective disorder diagnosis, paliperidone, and one additional required alternative.
    • Agitation/aggression: age 18 or older, severe symptoms requiring pharmacotherapy, qualifying cause, failed less-invasive management, and a qualifying acute-treatment pathway.
    Prior Authorization

    Reauthorization Required

    For continued treatment of agitation/aggression, reauthorization is required. Reauthorization is available for up to 14 days when the applicable continuation criteria are met.

    • Provide documentation that symptoms have responded, with improvement in agitation/aggression, but aggressive behavior is not yet fully resolved or controlled.
    Step Therapy

    Bipolar Disorder: One Alternative Required

    For bipolar disorder, document that the member is at least 10 years old, has bipolar disorder, and is unable to use or has tried and failed at least one listed formulary alternative.

    • Alternatives include aripiprazole, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.
    • When criteria are met, authorization may be approved for up to a lifetime.
    Step Therapy

    Schizophrenia: Two Alternatives Required

    For schizophrenia, document that the member is at least 18 years old, has schizophrenia, and is unable to use or has tried and failed two listed formulary alternatives.

    • Alternatives include aripiprazole, lurasidone, clozapine, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.
    • When criteria are met, authorization may be approved for up to a lifetime.
    Step Therapy

    Schizoaffective Disorder: Paliperidone Plus One Alternative

    For schizoaffective disorder, document that the member is at least 18 years old, has schizoaffective disorder, and is unable to use or has tried and failed paliperidone plus one additional listed alternative.

    • The additional alternative may be aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, or ziprasidone.
    • When criteria are met, authorization may be approved for up to a lifetime.
    Prior Authorization

    Agitation/Aggression: Acute Treatment Pathway

    For agitation/aggression associated with a psychiatric disorder, substance intoxication, or another organic cause, document severe symptoms requiring pharmacotherapy and failure of less-invasive management, such as verbal de-escalation. The member must either have been unable to use or have tried and failed a first-line immediate-acting intramuscular or inhaled medication, or have milder symptoms and be willing to take oral medication.

    • Examples of first-line immediate-acting treatment include aripiprazole IM, lorazepam IM, olanzapine IM, ziprasidone IM, or inhaled loxapine.
    • When criteria are met, initial authorization may be approved for up to 7 days.
    Documentation Required

    Clinical and Prior-Treatment Documentation Required

    Submit clinical and prior-treatment documentation supporting the request and any required formulary-alternative trials.

    • Up-to-date chart notes, relevant test results, and/or relevant imaging reports supporting the diagnosis.
    • Prescription claims records and/or prescription receipts supporting prior trials of formulary alternatives.
    Documentation Required

    Agitation/Aggression Chart Documentation Required

    For agitation/aggression requests, chart documentation must establish the symptoms and management supporting the criteria, including the severity and cause of the behavior and the response to prior management.

    • Describe the agitation/aggression symptoms and their severity.
    • Identify the associated psychiatric disorder, substance intoxication, or organic cause.
    • Document management attempted, including less-invasive strategies and acute treatment, and the member's response.
    Documentation Required

    Document Response for Continued Treatment

    For subsequent review of agitation/aggression treatment, document improvement in agitation/aggression symptoms while explaining that aggressive behavior remains incompletely resolved or controlled.

    Denial Risk

    Other Indications Are Unproven

    Asenapine (Saphris) for indications other than the covered indications and criteria described in the policy is considered experimental, investigational, or unproven.

    Denial Risk

    Brand Saphris Without Generic Failure May Be Denied

    A brand Saphris request may be denied when the record does not establish that the member is unable to use generic asenapine or has tried and failed generic asenapine.

    Denial Risk

    Insufficient Step Therapy May Result in Denial

    Requests may be denied when the required formulary step therapy is not satisfied or adequately documented.

    • Bipolar disorder requires inability to use or failure of one listed alternative.
    • Schizophrenia requires inability to use or failure of two listed alternatives.
    • Schizoaffective disorder requires inability to use or failure of paliperidone plus one additional listed alternative.
    Denial Risk

    Agitation/Aggression Criteria Must Be Established

    An agitation/aggression request may be denied when the record does not establish severe symptoms requiring pharmacotherapy, a qualifying cause, failure of less-invasive management, or a qualifying immediate-acting treatment pathway.

    • Document the symptoms, severity, cause, and management attempted.
    • Establish either failure or inability to use first-line immediate-acting intramuscular or inhaled medication, or milder symptoms with willingness to take oral medication.
    • Include chart documentation supporting all applicable criteria.
    Clinical urgencyEarly recognition and treatment is critical due to risks to both mother and infant.
    Schizophrenia
    DefinitionA psychiatric disorder involving chronic or recurrent psychosis.
    Common impactCommonly associated with impairments in social and occupational functioning.
    Policy relevanceSchizophrenia is an indication addressed by the asenapine (Saphris) coverage criteria.
    Schizoaffective disorder (ScAD)
    DefinitionA mental health condition with both psychotic symptoms and mood, or affective, disorder symptoms.
    Depressive symptomsMay include feeling sad or empty.
    Manic symptomsMay include raised mood or feeling powerful and able to do anything.
    Documentation
    DefinitionWritten information supporting the diagnosis or prior trials of formulary alternatives.
    Clinical recordsIncludes up-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses.
    Pharmacy recordsIncludes prescription claims records and/or prescription receipts to support prior trials of formulary alternatives.

    Postpartum psychosis

    Postpartum psychosis initial therapy requires ALL listed criteria.

    • ONE qualifying presentation: New-onset psychotic symptoms in the postpartum period; bipolar disorder with postpartum psychotic features; or a primary mental disorder with psychotic symptoms during the peripartum period.1 qualifying presentation

    Schizophrenia

    Schizophrenia initial therapy requires ALL listed criteria.

    • TWO listed alternatives: The member is unable to use, or has tried and failed, two of the following: aripiprazole, lurasidone, clozapine, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.2 alternatives

    Schizoaffective disorder

    Schizoaffective disorder initial therapy requires ALL listed criteria.

    • Required prior therapies

      • ONE additional alternative: The member is unable to use or has tried and failed one of the following: aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, or ziprasidone.Paliperidone plus 1 alternative

    Agitation/aggression

    Agitation/aggression initial therapy requires ALL listed criteria.

    • ONE medication-pathway condition: The member is unable to use, or has tried and failed, first-line immediate-acting intramuscular or inhaled medication when applicable; or the member has milder symptoms and is willing to take oral medication.1 of 2 conditions